Oral and intra-articular remedies: Review of papers published from March 2001 to February 2002.
There have been considerable advances in the drug treatments used to treat osteoarthritis. The development of selective cyclo-oxygenase inhibitors (COX-II) and confirmation of their efficacy and gastrointestinal safety will reduce treatment morbidity in the elderly. Guidelines for safe and appropriate use of COX-II drugs are now available. The role of anti-inflammatory drugs in precipitating cardiorenal events has been highlighted but remains to be fully evaluated. Glucosamine, diacerein, and hyaluronan may all be disease-modifying drugs for osteoarthritis but confirmatory studies are still needed.
Jubb
Ronald W
RW
University of Birmingham, Selly Oak Hospital, UK. Ronald.jubb@uhb.nhs.uk
D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D051546:Cyclooxygenase 2; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000139:chemically induced; D007270:Injections, Intra-Articular; D007527:Isoenzymes / Q000037:antagonists & inhibitors; D008565:Membrane Proteins; D010003:Osteoarthritis / Q000188:drug therapy*; D011451:Prostaglandin-Endoperoxide Synthases
D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D052246:Cyclooxygenase 2 Inhibitors; D016861:Cyclooxygenase Inhibitors; D007527:Isoenzymes; D008565:Membrane Proteins; D051546:Cyclooxygenase 2; C496540:PTGS2 protein, human; D011451:Prostaglandin-Endoperoxide Synthases